Scholar Rock Holding, a preclinical biotech targeting growth factor inhibition for a variety of diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol SRRK. Scholar Rock Holding filed confidentially on March 26, 2018. Jefferies, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
